Selected Publications

Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G.
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Arterioscler Thromb Vasc Biol 2018;38:592–598.

Morena M, Le May C, Chenine L, Arnaud L, Dupuy A-M, Pichelin M, Leray-Moragues H, Chalabi L, Canaud B, Cristol J-P, Cariou B.
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
J Clin Lipidol 2017;11:87–93

Laugier-Robiolle S, Vergès B, Le Bras M, Gand E, Bouillet B, Saulnier P-J, Le May C, Pichelin M, Maréchaud R, Petit J-M, Hadjadj S, Cariou B.
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes.
Diabetes Obes Metab 2017;19:448–451.

Joubert M, Jagu B, Montaigne D, Marechal X, Tesse A, Ayer A, Dollet L, Le May C, Toumaniantz G, Manrique A, Charpentier F, Staels B, Magré J, Cariou B, Prieur X.
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Diabetes 2017;66:1030–1040.

Si-Tayeb K, Idriss S, Champon B, Caillaud A, Pichelin M, Arnaud L, Lemarchand P, Le May C, Zibara K, Cariou B.
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Dis Model Mech 2016;9:81–90.

Dollet L, Levrel C, Coskun T, Le Lay S, Le May C, Ayer A, Venara Q, Adams AC, Gimeno RE, Magré J, Cariou* B, Prieur* X.
FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency.
Diabetes 2016;65:3410–3417.

Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM, ODYSSEY COMBO II Investigators.
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Eur Heart J 2015;36:1186-1194.

Bonnefond A, Yengo L, Le May C, Fumeron F, Marre M, Balkau B, Charpentier G, Franc S, Froguel P, Cariou B, DESIR study group.
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
Diabetologia 2015;doi:10.1007/s00125-015-3659-8.

Berger J-M, Vaillant N, Le May C, Calderon C, Brégeon J, Prieur X, Hadchouel J, Loirand G, Cariou B.
PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.
Atherosclerosis 2015;239:252-259.

Prieur X, Dollet L, Takahashi M, Nemani M, Pillot B, Le May C, Mounier C, Takigawa-Imamura H, Zelenika D, Matsuda F, Fève B, Capeau J, Lathrop M, Costet P, Cariou B, Magré J.
Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice.
Diabetologia 2013;56:1813-1825.

Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain MM, Collet X, Cariou B, Costet P.
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Arterioscler Thromb Vasc Biol 2013;33:1484-1493.